NEW YORK, April 9, 2018 /PRNewswire/ -- WallStEquities.com strives to bring the best free research to the investment community.Today we are offering reports on DXR, ELGX, GKOS, and HYH which can be accessed for free by signing up to www.wallstequities.com/registration. On Friday, April 06, 2018, US markets saw broad based losses with all sectors
On Friday, shares in New York headquartered Daxor Corp. recorded a trading volume of 82,600 shares. The stock ended the session 8.76% lower at $8.96. The Company's shares have gained 141.76% in the last month and 88.63% over the previous three months. The stock is trading above its 50-day and 200-day moving averages by 43.09% and 57.09%, respectively. Moreover, shares of Daxor, which provides biotechnology and cryobanking services in the US, have a Relative Strength Index (RSI) of 52.77. Get the full research report on DXR for free by clicking below at:
Irvine, California headquartered Endologix Inc.'s stock closed the day 2.99% lower at $4.22 with a total trading volume of 248,670 shares. The Company's shares have advanced 1.93% in the past month. The stock is trading above its 50-day moving average by 0.92%. Additionally, shares of Endologix, which develops, manufactures, markets, and sells medical devices for the treatment of abdominal aortic aneurysms in the US and internationally, have an RSI of 51.76. Free research on ELGX can be accessed at:
Shares in San Clemente, California headquartered Glaukos Corp. recorded a trading volume of 254,365 shares. The stock ended last Friday's trading session 1.78% lower at $31.38. The Company's shares have advanced 20.46% over the previous three months. The stock is trading above its 50-day moving average by 0.95%. Furthermore, shares of Glaukos, which focuses on the development and commercialization of surgical devices and sustained pharmaceutical therapies designed to treat glaucoma, have an RSI of 49.91. Sign up today for the free research report on GKOS at:
Alpharetta, Georgia headquartered Halyard Health Inc.'s stock finished Friday's session 1.47% higher at $46.12 with a total trading volume of 767,333 shares. The Company's shares have advanced 20.51% in the past twelve months. The stock is trading above its 200-day moving average by 2.32%. Additionally, shares of Halyard Health, which operates as a medical technology company that focuses on eliminating pain, speeding recovery, and preventing infection for healthcare providers and patients worldwide, have an RSI of 48.24.
On April 06th, 2018, research firm KeyBanc Capital Markets upgraded the Company's stock rating from 'Sector Weight' to 'Overweight'. Wall St. Equities' research coverage also includes the downloadable free report on HYH at:
Wall St. Equities:
Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
WSE has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email firstname.lastname@example.org. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
For any questions, inquiries, or comments reach out to us directly. If you're a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Email: email@example.com Phone number: +21-32-044-483Office Address: 1 Scotts Road #24-10, Shaw Center Singapore 228
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
View original content:http://www.prnewswire.com/news-releases/pre-market-technical-scan-on-medical-supplies-equities----daxor-endologix-glaukos-and-halyard-health-300626202.html
SOURCE Wall St. Equities
Subscribe to our Free Newsletters!